Benitec Biopharma Inc expected to post a loss of 35 cents a share - Earnings Preview

Benitec Biopharma

09/05/2025 15:36

Benitec Biopharma Inc BNTC.OQ BNTC.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Benitec Biopharma Inc is for a loss of 35 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Benitec Biopharma Inc is $28.00​, above​ its last closing price of $13.74. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.27
-0.77
-0.33
Beat
57.1
Sep. 30 2024
-0.50
-0.55
-0.48
Beat
12.7
Jun. 30 2024
-0.53
-0.49
-1.32
Missed
-170.4​
Mar. 31 2024
-0.78
-0.78
-1.64
Missed
-110
​​Dec. 31 2023
-0.39
-0.39
-2.64
Missed
-576.9
Sep. 30 2023
-0.51
-0.51
-2.76
Missed
-441.2​
Jun. 30 2023
-3.23
-2.83
Beat
12.3
Mar. 31 2023
-3.40
-3.40
-2.72
Beat
20

This summary was machine generated May 9 at 14:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)